EMAIL THIS PAGE TO A FRIEND

Redox biology

The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats.


PMID 28667906

Abstract

Hyperglycemia associated with inflammation and oxidative stress is a major cause of vascular dysfunction and cardiovascular disease in diabetes. Recent data reports that a selective sodium-glucose co-transporter 2 inhibitor (SGLT2i), empagliflozin (Jardiance